Protective effects of berberine on high fat-induced kidney damage by increasing serum adiponectin and promoting insulin sensitivity

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 11, 2015, Pages 14486-14492

  Wu, Yueyue ^a   Cha, Ying ^a   Huang, Xinmei ^a   Liu, Jun ^a   Chen, Zaoping ^a   Wang, Fang ^a   Xu, Jiong ^a   Sheng, Li ^a   Ding, Heyuan ^a  

^a Urology Institute of Fudan University   (China)

Author keywords

Adiponectin; AdipoR1; AdipoR2; Berberine; P AMPK

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1, RAT; ADIPONECTIN RECEPTOR 2, RAT; ADIPOQ PROTEIN, RAT; BERBERINE; C REACTIVE PROTEIN; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; TUMOR NECROSIS FACTOR;

ANIMAL; BLOOD; CELL PROTECTION; DISEASE MODEL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY; KIDNEY DISEASES; LIPID DIET; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR; UPREGULATION; WISTAR RAT;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BERBERINE; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CYTOPROTECTION; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; INSULIN; INSULIN RESISTANCE; KIDNEY; KIDNEY DISEASES; MALE; RATS, WISTAR; RECEPTORS, ADIPONECTIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 85013290756     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Moorhead J, El-Nahas M, Chan M and Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 320: 1309-1311.
2. Keane W, Kasiske B and O'Donnell M. Hyperlipidemia and the progression of renal disease. Am J Clin Nutr 1988; 47: 157-160.
3. Barnes B and Zierath J. Role of AMP-activated protein kinase in the control of glucose homeostasis. Curr Mol Med 2005; 5: 341-348.
4. Kahn BB, Alquier T, Carling D and Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
5. Patterson RE, Frank LL, Kristal AR and White E. A comprehensive examination of health conditions associated with obesity in older adults. Am J Prev Med 2004; 27: 385-390.
6. Vasseur F, Meyre D and Froguel P. Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert Rev Mol Med 2006; 8: 1-12.
7. Ho YT, Yang JS, Li TC, Lin JJ, Lin JG, Lai KC, Ma CY, Wood WG and Chung JG. Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and-9. Cancer Lett 2009; 279: 155-162.
8. Leng SH, Lu FE and Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 2004; 25: 496-502.
9. Rabbani GH. Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. Dan Med Bull 1996; 43: 173-185.
10. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK and Kim CT. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006; 55: 2256-2264.
11. Yin J, Gao Z, Liu D, Liu Z and Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008; 294: E148-E156.
12. Liu F, Chen HY, Huang XR, Chung AC, Zhou L, Fu P, Szalai AJ and Lan HY. C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes. Diabetologia 2011; 54: 2713-2723.
13. Tonelli M, Sacks F, Pfeffer M, Jhangri GS and Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-245.
14. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K and Tsunoda M. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
15. Sweiss N and Sharma K. Adiponectin effects on the kidney. Best Pract Res Clin Endocrinol Metab 2014; 28: 71-79.
16. Hallows KR, Mount PF, Pastor-Soler NM and Power DA. Role of the energy sensor AMPactivated protein kinase in renal physiology and disease. Am J Physiol Renal Physiol 2010; 298: F1067-F1077.
17. Declèves AE, Mathew AV, Cunard R and Sharma K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol 2011; 22: 1846-1855.
18. Hu Y, Fahmy H, Zjawiony JK and Davies GE. Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. Fitoterapia 2010; 81: 259-268.
19. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA and Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci U S A 2000; 97: 1433-1437.
20. Hsu CY, McCulloch CE, Iribarren C, Darbinian J and Go AS. Body mass index and risk for endstage renal disease. Ann Inter Med 2006; 144: 21-28.
21. Lin J, Judd S, Le A, Ard J, Newsome BB, Howard G, Warnock DG and McClellan W. Associations of dietary fat with albuminuria and kidney dysfunction. Am J Clin Nutr 2010; 92: 897-904.
22. Oh J and Rabb H. Adiponectin: an enlarging role in acute kidney injury. Kidney Int 2013; 83: 546-548.